Association between late-onset hypogonadism syndrome plus metabolic syndrome and prostate cancer and its aggressiveness

To assess the relationship between prostate cancer (PC) and the presence of metabolic syndrome and late-onset hypogonadism (LOH) syndrome.

A retrospective study was conducted on 686 patients who underwent prostate biopsy.

We analysed the demographic variables, clinical data and biopsy results. To diagnose metabolic syndrome, we employed the criteria of the American Heart Association. For the diagnosis of LOH syndrome, we employed the Androgen Deficiency in the Aging Male questionnaire and testosterone levels (TT). We evaluated the relationship between free testosterone (FT) and bioavailable testosterone (BT) on one hand and PC and its aggressiveness on the other, as well as the usefulness of the TT to prostate specific antigen (TT/PSA) ratio in the PC diagnosis.

The patient's median age was 65 years. Metabolic syndrome is not associated with PC (39.4% vs. 35%; P=.1) but is associated with a PC Gleason score >7 (50.4% vs. 29.44%; P=.002). LOH, low FT and low BT are associated with an increased presence of PC (51% vs. 35%, P=.02; 44.86% vs. 33.33%, P=.03; and 46.46% vs. 33.08%, P=.01, respectively) and with an increased probability of a PC Gleason score >7 (61.54% vs. 37.5%, P=.02; 54.17% vs. 34.12%, P=.02; 54.35% vs. 34.48%, P=.02, respectively). Additionally, the median TT/PSA ratio was significantly lower in patients with positive biopsies (P=.022).

Metabolic syndrome was not associated with the probability of having PC but was associated with a PC Gleason score >7. Moreover, LOH syndrome had a higher percentage of PC and a greater presence of PC Gleason scores >7, as did low levels of FT and low levels of BT.

Actas urologicas espanolas. 2016 Apr 15 [Epub ahead of print]

J Fuentes-Pastor, P Pellejero, I Ortiz, M Ramírez-Backhaus, A de Gracia, C Marrugo, A Gomez-Ferrer, A Calatrava, J Rubio-Briones, C Rodriguez-Torreblanca, E Solsona-Narbón

Servicio de Urología, Hospital Universitario de Marqués de Valdecilla (HUMV), Santander, España., Servicio de Urología, Hospital Universitario Central de Asturias (HUCA), Oviedo, España., Departamento de Matemática Aplicada, Universidad de Almería, Almería, España., Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España. Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España., Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España., Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España., Servicio de Anatomía Patológica, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España., Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España., Departamento de Matemática Aplicada, Universidad de Almería, Almería, España., Servicio de Urología, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe